Kineret

KINERET is an interleukin-1 receptor antagonist indicated for:

• Reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more disease modifying antirheumatic drugs (DMARDs) (
  
  1.1)
  

• Treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID) (
  
  1.2)
  

• Treatment of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) (
  
  1.3)
  

• The recommended dose of KINERET for the treatment of patients with rheumatoid arthritis is 100 mg/day administered daily by subcutaneous injection. The dose should be administered at approximately the same time every day (
  
  2.1)
  
• Physicians should consider a dose of 100 mg of KINERET administered every other day for RA patients who have severe renal insufficiency or end stage renal disease (defined as creatinine clearance < 30 mL/min, as estimated from serum creatinine levels) (
  
  2.4)
  

• The recommended starting dose of KINERET is 1-2 mg/kg daily for NOMID patients. The dose can be individually adjusted to a maximum of 8 mg/kg daily to control active inflammation. (
  
  2.2)
  
• Physicians should consider administration of the prescribed KINERET dose every other day for NOMID patients who have severe renal insufficiency or end stage renal disease (defined as creatinine clearance < 30 mL/min, as estimated from serum creatinine levels) (
  
  2.4)
  

• The recommended starting dose of KINERET is 1-2 mg/kg daily for patients with DIRA. The dose can be individually adjusted to a maximum of 8 mg/kg daily to control active inflammation. (
  
  2.3)
  
• Physicians should consider administration of the prescribed KINERET dose every other day for patients with DIRA who have severe renal insufficiency or end stage renal disease (defined as creatinine clearance < 30 mL/min, as estimated from serum creatinine levels) (
  
  2.4)
  

See full prescribing information for administration instructions (
2.4)

Injection: 100 mg/0.67 mL solution in a single-use prefilled syringe for subcutaneous injection. Graduated syringe allows for doses between 20 and 100 mg.

• Pediatric use: KINERET is indicated for use in pediatric patients with NOMID and DIRA (
  
  8.4)
  
• Geriatric use: Because there is a higher incidence of infections in the elderly population in general, caution should be used in treating the elderly (
  
  8.5)
  
• Renal impairment: This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function (
  
  8.6)